Which intervention is LEAST likely to improve this patient's hemodynamics in hypertrophic obstructive cardiomyopathy during surgery?

Which intervention is LEAST likely to improve this patient's hemodynamics in hypertrophic obstructive cardiomyopathy during surgery?

• A. Administration of esmolol
• B. Fluid bolus
• C. Dobutamine infusion
• D. Administration of phenylephrine

Answer: (C)

In hypertrophic obstructive cardiomyopathy, the pressure gradient across the left ventricular outflow tract is dynamic and highly sensitive to contractility, preload, and afterload. Treatments that lower contractility or increase preload or afterload tend to lessen the obstruction and improve hemodynamics. Es molol works by slowing the heart and reducing myocardial contractility, which diminishes the systolic narrowing and the gradient, helping forward flow. Giving a fluid bolus increases preload, which enlarges the left ventricular cavity during systole and reduces the contact between the septum and the mitral valve, also easing the obstruction. Phenylephrine raises afterload and systemic vascular resistance, which can shift the flow dynamics to lessen the outflow tract gradient and improve perfusion. Dobutamine, on the other hand, increases contractility and often heart rate. In HOCM this tends to amplify the dynamic obstruction by shrinking the LV cavity during systole and worsening the LVOT gradient, making hemodynamics worse rather than better. So this agent is least likely to improve the situation. In short, manipulating contractility and afterload to reduce the LVOT gradient is the goal, and dobutamine runs counter to that aim by enhancing inotropy and reducing the ease of outflow.

In hypertrophic obstructive cardiomyopathy, the pressure gradient across the left ventricular outflow tract is dynamic and highly sensitive to contractility, preload, and afterload. Treatments that lower contractility or increase preload or afterload tend to lessen the obstruction and improve hemodynamics.

Es molol works by slowing the heart and reducing myocardial contractility, which diminishes the systolic narrowing and the gradient, helping forward flow. Giving a fluid bolus increases preload, which enlarges the left ventricular cavity during systole and reduces the contact between the septum and the mitral valve, also easing the obstruction. Phenylephrine raises afterload and systemic vascular resistance, which can shift the flow dynamics to lessen the outflow tract gradient and improve perfusion.

Dobutamine, on the other hand, increases contractility and often heart rate. In HOCM this tends to amplify the dynamic obstruction by shrinking the LV cavity during systole and worsening the LVOT gradient, making hemodynamics worse rather than better. So this agent is least likely to improve the situation.

In short, manipulating contractility and afterload to reduce the LVOT gradient is the goal, and dobutamine runs counter to that aim by enhancing inotropy and reducing the ease of outflow.